Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 139 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the... March 26, 2021 Researchers Have Discovered How Fat Cells Fuel The Spread Of Breast... December 19, 2019 FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML June 13, 2022 After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby November 25, 2020 Load more HOT NEWS Grieving for Your Old Life After Cancer ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials New insights on self-sampling for cervical cancer screening
